Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study.


Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 05 08 2019
accepted: 04 12 2020
pubmed: 5 1 2021
medline: 20 4 2021
entrez: 4 1 2021
Statut: ppublish

Résumé

To investigate men's experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial. A longitudinal qualitative interview study was embedded in the ProtecT RCT. Sixteen men with clinically LPCa who underwent EBRT in ProtecT were purposively sampled to include a range of socio-demographic and clinical characteristics. They participated in serial in-depth qualitative interviews for up to 8 years post-treatment, exploring experiences of treatment and its side effects over time. Men experienced bowel, sexual, and urinary side effects, mostly in the short term but some persisted and were bothersome. Most men downplayed the impacts, voicing expectations of age-related decline, and normalizing these changes. There was some reticence to seek help, with men prioritizing their relationships and overall health and well-being over returning to pretreatment levels of function. Some unmet needs with regard to information about treatment schedules and side effects were reported, particularly among men with continuing functional symptoms. These findings reinforce the importance of providing universal clear, concise, and timely information and supportive resources in the short term, and more targeted and detailed information and care in the longer term to maintain and improve treatment experiences for men undergoing EBRT.

Identifiants

pubmed: 33394204
doi: 10.1007/s10552-020-01380-3
pii: 10.1007/s10552-020-01380-3
pmc: PMC7870600
doi:

Substances chimiques

Androgen Antagonists 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

261-269

Subventions

Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Health Technology Assessment Programme
ID : 96/20/06
Organisme : Health Technology Assessment Programme
ID : 96/20/99

Investigateurs

P Holding (P)
J W F Catto (JWF)
D J Rosario (DJ)
H Kynaston (H)
O Hughes (O)
P Bollina (P)
A Doherty (A)
V Gnanapragasam (V)
R Kockelbergh (R)
A Paul (A)
E Paez (E)
D Gillatt (D)
E Rowe (E)
J Oxley (J)

Références

J Behav Med. 2005 Jun;28(3):281-93
pubmed: 16015462
N Engl J Med. 2012 Jul 19;367(3):203-13
pubmed: 22808955
Eur J Cancer Care (Engl). 2015 Sep;24(5):618-34
pubmed: 25630851
BMJ. 2009 Sep 28;339:b3702
pubmed: 19786485
Med Care. 2003 Aug;41(8):923-36
pubmed: 12886172
BMC Urol. 2014 Jul 30;14:56
pubmed: 25073798
J Wound Ostomy Continence Nurs. 2012 Jan-Feb;39(1):90-4
pubmed: 22089764
Health Technol Assess. 2003;7(14):1-88
pubmed: 12709289
J Health Psychol. 2002 May;7(3):303-16
pubmed: 22114252
Nurse Res. 2006 Jul 1;13(4):84
pubmed: 27702218
Palliat Support Care. 2013 Aug;11(4):331-9
pubmed: 23013742
Soc Sci Med. 2006 Aug;63(4):911-9
pubmed: 16798130
Lancet Oncol. 2014 Sep;15(10):1109-18
pubmed: 25163905
Health Technol Assess. 2020 Aug;24(37):1-176
pubmed: 32773013
Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e92-e100
pubmed: 27425582
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54
pubmed: 18695132
Soc Sci Med. 1973 Sep;7(9):677-89
pubmed: 4749058
Eur J Cancer Care (Engl). 2016 Jan;25(1):180-9
pubmed: 25523386
Eur J Cancer Care (Engl). 2004 Jul;13(3):272-8
pubmed: 15196231
JAMA. 2017 Mar 21;317(11):1126-1140
pubmed: 28324093
JAMA. 2017 Mar 21;317(11):1141-1150
pubmed: 28324092
Soc Sci Med. 2017 Jul;185:17-26
pubmed: 28549250
Patient Educ Couns. 2011 Aug;84(2):200-7
pubmed: 20702055

Auteurs

E Sutton (E)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.

J A Lane (JA)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.
Bristol Randomised Trials Collaboration, Population Health Sciences, Bristol Medical School, Canynge Hall, 39 Whatley Road, Clifton, Bristol, BS8 2PS, UK.

M Davis (M)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.

E I Walsh (EI)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.

D E Neal (DE)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

F C Hamdy (FC)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

M Mason (M)

Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.

J Staffurth (J)

Department of Oncology, Cardiff University, Cardiff, UK.

R M Martin (RM)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.

C Metcalfe (C)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.

T J Peters (TJ)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.

J L Donovan (JL)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK.
National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) West, University Hospitals Bristol NHS Trust, Bristol, UK.

J Wade (J)

Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK. julia.wade@bristol.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH